Various pharmacological agents in the pipeline against intractable epilepsy.
clinical trials
drug development
epilepsy
intractable epilepsy
pharmacological agents
Journal
Archiv der Pharmazie
ISSN: 1521-4184
Titre abrégé: Arch Pharm (Weinheim)
Pays: Germany
ID NLM: 0330167
Informations de publication
Date de publication:
20 May 2024
20 May 2024
Historique:
revised:
25
04
2024
received:
27
03
2024
accepted:
29
04
2024
medline:
20
5
2024
pubmed:
20
5
2024
entrez:
20
5
2024
Statut:
aheadofprint
Résumé
Epilepsy is a noncommunicable chronic neurological disorder affecting people of all ages, with the highest prevalence in low and middle-income countries. Despite the pharmacological armamentarium, the plethora of drugs in the market, and other treatment options, 30%-35% of individuals still show resistance to the current medication, termed intractable epilepsy/drug resistance epilepsy, which contributes to 50% of the mortalities due to epilepsy. Therefore, the development of new drugs and agents is needed to manage this devastating epilepsy. We reviewed the pipeline of drugs in "ClinicalTrials. gov," which is the federal registry of clinical trials to identify drugs and other treatment options in various phases against intractable epilepsy. A total of 31 clinical trials were found regarding intractable epilepsy. Among them, 48.4% (15) are about pharmacological agents, of which 26.6% are in Phase 1, 60% are in Phase 2, and 13.3% are in Phase 3. The mechanism of action or targets of the majority of these agents are different and are more diversified than those of the approved drugs. In this article, we summarized various pharmacological agents in clinical trials, their backgrounds, targets, and mechanisms of action for the treatment of intractable epilepsy. Treatment options other than pharmacological ones, such as devices for brain stimulation, ketogenic diets, gene therapy, and others, are also summarized.
Identifiants
pubmed: 38767508
doi: 10.1002/ardp.202400229
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2400229Informations de copyright
© 2024 Deutsche Pharmazeutische Gesellschaft.
Références
(WHO), W.H.O. Epilpesy. 2024. https://www.who.int/news-room/fact-sheets/detail/epilepsy
R. M. Kaminski, M. A. Rogawski, H. Klitgaard, Neurotherapeutics 2014, 11(2), 385.
W. Löscher, H. Potschka, S. M. Sisodiya, A. Vezzani, Pharmacol. Rev. 2020, 72(3), 606.
E. Perucca, P. Perucca, H. S. White, E. C. Wirrell, Lancet Neurol. 2023, 22, 723.
J. Falco‐Walter, Seminars in Neurology, Thieme Medical Publishers, Inc, 2020, 40(6), 617.
R. D. Thijs, R. Surges, T. J. O'Brien, J. W. Sander, Lancet 2019, 393(10172), 689.
W. L. Shorvon, D. Schmidt, The Treatment of Epilepsy, The Atrium, Southern Gate, Chichester, West Sussex, UK 2015, https://onlinelibrary.wiley.com/doi/abs/10.1002/9781118936979.ch7
E. Perucca, Acta Epileptol. 2021, 3(1), 22.
W. Löscher, P. Klein, CNS Drugs 2021, 35(9), 935.
E. Perucca, T. Tomson, Lancet Neurol. 2011, 10(5), 446.
epilepsy, c. Epilepsy medication list. 2024. Accessed April 20, 2024. https://cureepilepsy.org/for-patients/understanding/treatments/epilepsy-medications/?utm_source=google&utm_medium=cpc&utm_campaign=understanding_epilepsy&utm_campaign=1033990312&utm_source=google&utm_medium=cpc&utm_content=656441533660&utm_term=epilepsy%20medication&adgroupid=146872950205&gad_source=1&gclid=Cj0KCQjwzZmwBhD8ARIsAH4v1gVJSkdTT_km0S4OeWDyBCBMDaYT4nuebumlVF12kJpXExiFX5qc_2YaAgfOEALw_wcB
A. Waris, A. Ullah, M. Asim, R. Ullah, M. d. R. Rajdoula, S. T. Bello, F. A. Alhumaydhi, Front. Pharmacol. 2024. In press. https://doi.org/10.3389/fphar.2024.1403232
B. Wright, Clinical Trial Phases, In A Comprehensive And Practical Guide To Clinical Trials, Elsevier, Oxford, UK 2017, pp. 11.
Registry, N.I.o.H.N.c.r. ClinicalTrials.gov. Accessed March 15, 2024. https://www.clinicaltrials.gov/search?cond=Epilepsy%20Intractable
S. A. Miratashi Yazdi, M. Abbasi, S. M. Miratashi Yazdi, Rev. Neurosci. 2017, 28(2), 185.
A. M. Mahfoz, N. Shahzad, Behav. Pharmacol. 2019, 30(8), 660.
D. L. Teagarden, K. J. Meador, D. W. Loring, Epilepsy Res. 2014, 108(8), 1352.
A. N. Cebeci, B. Ekici, Expert. Rev. Neurother. 2014, 14(5), 481.
A. M. Mahfoz, A. F. Abdel‐Wahab, M. A. Afify, N. Shahzad, I. A. A. Ibrahim, N. A. ElSawy, G. A. Bamagous, S. S. Al Ghamdi, Naunyn‐Schmiedeberg's Arch. Pharmacol. 2017, 390, 977.
C. M. DeGiorgio, D. Hertling, A. Curtis, D. Murray, D. Markovic, Epilepsy Behav. 2019, 94, 195.
A. Hosseinzadeh, E. Dehdashtian, M. Jafari‐Sabet, S. Mehrzadi, Cent. Nerv. Syst. Agents Med. Chem. 2022, 22(2), 118.
X. Jiang, Y. Wang, J. Liu, Int. J. Mass Spectrom. 2022, 481, 116912.
H. Jiang, S. Zhang, Iran. J. Basic Med. Sci. 2022, 25(1), 84.
R. Akkaya, B. Akkaya, R. O. Bello, J. Mol. Struct. 2023, 1273, 134246.
A. Holló, Z. Clemens, A. Kamondi, P. Lakatos, A. Szűcs, Epilepsy Behav. 2012, 24(1), 131.
M.‐T. Yang, I.‐C. Chou, H.‐S. Wang, Epilepsy Behav. 2023, 139, 109062.
H. M. Alhaidari, F. Babtain, K. Alqadi, A. Bouges, S. Baeesa, Y. A. Al‐Said, Ann. Saudi. Med. 2022, 42(4), 262.
S. Gharehaghaji, Y. Panahi, E. Khalilzadeh, G. Saiah, Res. Pharm. Sci. 2023, 18(1), 59.
R. O. Da Costa, C. V. J. Gadelha‐Filho, P. E. A. de Aquino, L. A. R. Lima, J. D. de Lucena, W. L. C. Ribeiro, F. A. V. Lima, K. R. T. Neves, G. S. de Barros Viana, Neurochem. Res. 2023, 48(1), 142.
M. Farghali, S. Ruga, V. Morsanuto, F. Uberti, Brain Sci. 2020, 10(9), 660.
S. G. Menéndez, W. Manucha, Curr. Pharm. Des. 2024, 30(5), 323.
H. Jiang, X. Yang, Y. Wang, C. Zhou, BioMed Res. Int. 2022, 2022, 1.
C. M. Lienberger, A Candidate Drug Screen of Compounds that Modulate EBNA2 Expression, University of Cincinnati, Ohio, USA 2019.
W. Zhao, C. Xie, X. Zhang, J. Liu, J. Liu, Z. Xia, Brain Behav. 2023, 13(6), e2995.
J. Okoh, J. Mays, A. Bacq, J. A. Oses‐Prieto, S. Tyanova, C. J. Chen, K. Imanbeyev, M. Doladilhe, H. Zhou, P. Jafar‐Nejad, A. Burlingame, J. Noebels, S. Baulac, M. Costa‐Mattioli, Nat. Commun. 2023, 14(1), 7364.
A. Gerasimenko, S. Baldassari, S. Baulac, Neurobiol. Dis. 2023, 182, 106144.
M. Khademi, F. Moradkhani, F. S. Hosseini, M. Asadi, A. Amanlou, R. Khorasani, A. B. Morgani, M. Amanlou, J. Iran. Chem. Soc. 2022, 19, 2467.
J. B. Stephenson, Dev. Med. Child Neurol. 1976, 18(2), 189.
B. Payandemehr, R. Rahimian, M. Gooshe, A. Bahremand, R. Gholizadeh, S. Berijani, M. Ahmadi‐Dastgerdi, M. Aminizade, A. Sarreshte‐Dari, V. Dianati, M. Amanlou, A. R. Dehpour, Epilepsy Behav. 2014, 34, 99.
P. Ahuja, A. Husain, N. Siddiqui, Med. Chem. Res. 2014, 23, 4085.
W. Lenz, Thalidomide and congenital abnormalities, in Problems of Birth Defects: From Hippocrates to Thalidomide and After, Springer, Lancaster, UK 1962, pp. 199.
A. M. Islas‐Espinoza, C. Campos‐Rodriguez, E. R. San Juan, J. Toxicol. Sci. 2018, 43(11), 671.
I. M. Cumbres‐Vargas, S. R. Zamudio, L. A. Pichardo‐Macías, E. Ramírez‐San Juan, Int. J. Mol. Sci. 2023, 24(7), 6488.
A. Amanlou, F. Eslami, M. Shayan, P. Mortazavi, A. Dehpour, Res. Pharm. Sci. 2021, 16(6), 586.
G. Palencia, I. E. Martinez‐Juarez, A. Calderon, C. Artigas, J. Sotelo, Epilepsy Res. 2010, 92(2–3), 253.
G. Padmanabhan, I. Becue, J. B. Smith, in Analytical profiles of drug substances, Academic Press Limited, London Elsevier, 1990, pp. 57.
S. R. Bareggi, U. Cornelli, CNS Neurosci. Ther. 2012, 18(1), 41.
A. Budimir, Acta Pharm. 2011, 61(1), 1.
A. Takeda, Brain Res. Rev. 2000, 34(3), 137.
P. Paoletti, A. M. Vergnano, B. Barbour, M. Casado, Neuroscience 2009, 158(1), 126.
A. R. Kay, K. Tóth, Sci. Signaling 2008, 1(19), re3.
C. Zavala‐Tecuapetla, M. Cuellar‐Herrera, H. Luna‐Munguia, Int. J. Mol. Sci. 2020, 21(22), 8573.
A. Rosati, S. De Masi, R. Guerrini, CNS Drugs 2018, 32, 997.
J. A. Hudetz, P. S. Pagel, J. Cardiothorac. Vasc. Anesth. 2010, 24(1), 131.
Y. Fang, X. Wang, Seizure 2015, 30, 14.
L. C. Chang, S. R. Raty, J. Ortiz, N. S. Bailard, S. J. Mathew, CNS Neurosci. Ther. 2013, 19(6), 390.
A. S. Synowiec, D. S. Singh, V. Yenugadhati, J. P. Valeriano, C. J. Schramke, K. M. Kelly, Epilepsy Res. 2013, 105(1–2), 183.
N. Gaspard, B. Foreman, L. M. Judd, J. N. Brenton, B. R. Nathan, B. M. McCoy, A. Al‐Otaibi, R. Kilbride, I. S. Fernández, L. Mendoza, S. Samuel, A. Zakaria, G. P. Kalamangalam, B. Legros, J. P. Szaflarski, T. Loddenkemper, C. D. Hahn, H. P. Goodkin, J. Claassen, L. J. Hirsch, S. M. LaRoche, Epilepsia 2013, 54(8), 1498.
M. García‐Ruiz, P. M. Rodríguez, L. Palliotti, C. Lastras, M. Romeral‐Jiménez, I. G. Morales, C. P. Rey, M. Rodrigo‐Gisbert, D. Campos‐Fernández, E. Santamarina, B. P. Carbonell, Seizure 2024, 117, 13.
H. A. Mucke, Pharm. Pat. Anal. 2022, 11(1), 1.
J.‐N. Dohrke, J. F. Watson, K. Birchall, I. H. Greger, J. Biol. Chem. 2020, 295(43), 14565.
T. J. O'Brien, J. Germaine, J. P. Nicolo, P. Perucca, S. Mullen, D. Reutens, B. Wharrie, H. Robinson, B. Walsh, A. Roten, L. Millist, E. Foster, S. Hosking, S. Chamorro, A. Bates, R. Niecestro, BMJ Neurol. Open. 2022, 4, A1–A68.
M. Wood, V. Daniels, L. Provins, C. Wolff, R. M. Kaminski, M. Gillard, J. Pharmacol. Exp. Ther. 2020, 372(1), 1.
M. Rademacher, M. Toledo, W. Van Paesschen, K. K. Liow, I. G. Milanov, M. L. Esch, N. Wang, M. MacPherson, W. J. Byrnes, T. D. C. Minh, E. Webster, K. J. Werhahn, Epilepsia Open 2022, 7(4), 758.
Trials, c. Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal‐onset Seizures in Adults With Drug‐resistant Epilepsy (ARISE) 2024. Accessed April 21,2024. https://www.clinicaltrials.gov/study/NCT03373383?term=NCT03373383&rank=1&tab=results
J. Amlerova, J. Šroubek, F. Angelucci, J. Hort, Int. J. Mol. Sci. 2021, 22(11), 5576.
S. Chatzikonstantinou, G. Gioula, V. K. Kimiskidis, J. McKenna, I. Mavroudis, D. Kazis, Epilepsia Open 2021, 6(1), 28.
A. Peng, X. Qiu, W. Lai, W. Li, L. Zhang, X. Zhu, S. He, J. Duan, L. Chen, Epilepsy Res. 2018, 147, 102.
H. Lee, S. Lee, D. H. Lee, D. W. Kim, Epilepsy Res. 2021, 172, 106601.
C. Ceccarani, I. Viganò, E. Ottaviano, M. G. Redaelli, M. Severgnini, A. Vignoli, E. Borghi, Microbiology 2021, 11, 749509.
M. Gómez‐Eguílaz, J. L. Ramón‐Trapero, L. Pérez‐Martínez, J. R. Blanco, Benef. Microbes 2018, 9(6), 875.
X. Gong, X. Liu, C. Chen, J. Lin, A. Li, K. Guo, D. An, D. Zhou, Z. Hong, Front. Microbiol. 2020, 11, 517797.
A. Arulsamy, Q. Y. Tan, V. Balasubramaniam, T. J. O'Brien, M. F. Shaikh, ACS Chem. Neurosci. 2020, 11(21), 3488.
M. Dahlin, S. S. Singleton, J. A. David, A. Basuchoudhary, R. Wickström, R. Mazumder, S. Prast‐Nielsen, EBioMedicine 2022, 80, 104061.
M. Malach, I. Kovalchuk, O. Kovalchuk, Pharmaceuticals 2022, 15(3), 359.
S. C. Britch, S. Babalonis, S. L. Walsh, Psychopharmacology 2021, 238, 9.
J. Atsmon, D. Heffetz, L. Deutsch, F. Deutsch, H. Sacks, Clin. Pharmacol. Drug Dev. 2018, 7(7), 751.
A. Mitelpunkt, U. Kramer, M. Hausman Kedem, E. Zilbershot Fink, R. Orbach, V. Chernuha, A. Fattal‐Valevski, L. Deutsch, D. Heffetz, H. Sacks, Epilepsy Behav. 2019, 98, 233.
M. Arakawa, Y. Ito, Cerebellum 2007, 6(4), 308.
E. Mohammadi, F. Nikbakht, S. Vazifekhah, J. F. Babae, M. T. Jogataei, Behav. Brain Res. 2023, 440, 114263.
B. Pedre, U. Barayeu, D. Ezeriņa, T. P. Dick, Pharmacol. Ther. 2021, 228, 107916.
C. Bilister Egilmez, B. Azak Pazarlar, M. A. Erdogan, O. Erbas, Epilepsy Res. 2023, 193, 107144.
M. Efendioglu, R. Basaran, M. Akca, D. Ceman, C. Demirtas, M. Yildirim, Neurochem. Res. 2020, 45(8), 1802.
R. Chitolina, C. G. Reis, T. Stahlhofer‐Buss, A. Linazzi, R. Benvenutti, M. Marcon, A. P. Herrmann, A. Piato, Pharmacol. Reports 2023, 75(6), 1544.
J. Bhatti, B. Nascimento, U. Akhtar, S. G. Rhind, H. Tien, A. Nathens, L. T. da Luz, Front. Neurol. 2018, 8, 323619.
K. Ibhazehiebo, C. Gavrilovici, C. L. de la Hoz, S. C. Ma, R. Rehak, G. Kaushik, P. L. Meza Santoscoy, L. Scott, N. Nath, D. Y. Kim, J. M. Rho, D. M. Kurrasch, Brain 2018, 141(3), 744.
N. Durisic, A. Keramidas, C. L. Dixon, J. W. Lynch, Front. Mol. Neurosci. 2018, 11, 89.
D. Kurrasch 2018, Alberta Health Services, PROTOCOL NO. VOR‐17‐2471, 2018.
R. Citraro, A. Leo, M. Santoro, G. D'agostino, A. Constanti, E. Russo, Curr. Pharm. Des. 2018, 23(37), 5546.
R. Citraro, A. Leo, C. De Caro, V. Nesci, M. E. Gallo Cantafio, N. Amodio, G. Mattace Raso, A. Lama, R. Russo, A. Calignano, M. Tallarico, E. Russo, G. De Sarro, Mol. Neurobiol. 2020, 57, 408.
A. Srivastava, J. Banerjee, V. Dubey, M. Tripathi, P. S. Chandra, M. C. Sharma, S. Lalwani, F. Siraj, R. Doddamani, A. B. Dixit, Cell. Mol. Neurobiol. 2022, 42, 1049.
S. Ahmad Ganai, M. Ramadoss, V. Mahadevan, Curr. Neuropharmacol. 2016, 14(1), 55.
B. E. Morrison, N. Majdzadeh, S. R. D'mello, Cell. Mol. Life Sci. 2007, 64, 2258.
A. M. Poff, J. M. Rho, D. P. D'Agostino, Front. Neurosci. 2019, 13, 439318.
Z. Kovács, D. P. D'Agostino, D. M. Diamond, C. Ari, Front. Mol. Neurosci. 2019, 12, 45.
R. L. Veech, J. Lipid Res. 2014, 55(10), 2004.
J. Whitfield, Med. Sci. Sports Exerc. 2021, 53(4), 776–784.
S. L. Ciarlone, J. C. Grieco, D. P. D'Agostino, E. J. Weeber, Neurobiol. Dis. 2016, 96, 38.
A. Gil‐Nagel, M. J. Brodie, R. Leroy, T. Cyr, S. Hall, M. Castiglia, C. Twomey, K. VanLandingham, Epilepsy Res. 2012, 102(1–2), 117.
T. V. Wuttke, G. Seebohm, S. Bail, S. Maljevic, H. Lerche, Mol. Pharmacol. 2005, 67(4), 1009.
M. Ossemann, K. de Fays, B. Bihin, Y. Vandermeeren, Epilepsy Res. 2016, 126, 78.
GlaxoSmithKline. Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy (RESTORE1). https://www.clinicaltrials.gov/study/NCT00232596?term=retigabine%2F%20ezogabine&rank=25&tab=results
GLAXOSMITHKLINE. Glaxosmithkline: trobalt®/potiga® discontinuation ‐important reminder. 2017. Accessed April 20, 2024. https://www.ilae.org/files/dmfile/GSK_RetigabineTrobalt-Reminder.pdf
NeurologyLive. Anticonvulsant Potiga Discontinued in June 2017. Accessed April 20, 2024. https://www.neurologylive.com/view/anticonvulsant-potiga-discontinued-june-2017
Xenon, Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2‐DEE Before Year‐End, J. RegtsEditor. 2020. https://financialpost.com/pmn/press-releases-pmn/globe-newswire-releases/xenon-pharmaceuticals-receives-fda-feedback-and-is-on-track-to-initiate-xen496-phase-3-clinical-trial-for-the-treatment-of-kcnq2-dee-before-year-end-positive-opinion-received-supporting-orphan-medicin
Xenon, Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update, J. RegtsEditor. 2023. https://www.biospace.com/article/releases/xenon-pharmaceuticals-receives-fda-feedback-and-is-on-track-to-initiate-xen496-phase-3-clinical-trial-for-the-treatment-of-kcnq2-dee-before-year-end/
S. Lattanzi, E. Trinka, S. Meletti, P. Striano, S. Matricardi, M. Silvestrini, F. Brigo, Expert Rev. Clin. Pharmacol. 2024, 117,90–97.
J. J. Fan, W. Shan, J. P. Wu, Q. Wang, CNS Neurosci. Ther. 2019, 25(11), 1222.
A. P. Amar, Expert. Rev. Neurother. 2007, 7(12), 1763.
S. Klinkenberg, M. W. Aalbers, J. S. Vles, E. M. Cornips, K. Rijkers, L. Leenen, F. G. Kessels, A. P. Aldenkamp, M. Majoie, Dev. Med. Child Neurol. 2012, 54(9), 855.
P. Tanganelli, S. Ferrero, P. Colotto, G. Regesta, Clin. Neurol. Neurosurg. 2002, 105(1), 9.
M. S. Markert, R. S. Fisher, Expert. Rev. Neurother. 2019, 19(1), 17.
R. S Terry Jr., Epilepsy Topics, InTech, Rijeka, Croatia 2014, pp. 139.
J. Yang, J. H. Phi, J. Korean Neurosurg. Soc. 2019, 62(3), 344.
E. Desli, M. Spilioti, A. Evangeliou, F. Styllas, F. Magkos, M. Dalamaga, Curr. Nutr. Rep. 2022, 11(2), 102.
V. Sondhi, A. Agarwala, R. M. Pandey, B. Chakrabarty, P. Jauhari, R. Lodha, G. S. Toteja, S. Sharma, V. K. Paul, E. Kossoff, S. Gulati, JAMA Pediatr. 2020, 174(10), 944.
H. C. Kang, D. E. Chung, D. W. Kim, H. D. Kim, Epilepsia 2004, 45(9), 1116.
A. A. Shaimardanova, D. S. Chulpanova, A. I. Mullagulova, Z. Afawi, R. G. Gamirova, V. V. Solovyeva, A. A. Rizvanov, Front. Mol. Neurosci. 2022, 15, 868531.
A. Snowball, E. Chabrol, R. C. Wykes, T. Shekh‐Ahmad, J. H. Cornford, A. Lieb, M. P. Hughes, G. Massaro, A. A. Rahim, K. S. Hashemi, D. M. Kullmann, M. C. Walker, S. Schorge, J. Neurosci. 2019, 39(16), 3159.
J. Cummings, G. Lee, P. Nahed, M. Kambar, K. Zhong, J. Fonseca, K. Taghva, Alzheimer's Dement. 2022, 8(1), 12295.
Gribkoff, V. K. and L. K. Kaczmarek, Neuropharmacology, 2017. 120: p. 11.